Krause Kenneth D.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
UBS and JPMorgan Cut Rollins Price Targets Ahead of Earnings. Rollins is set to report its third-quarter earnings next week, drawing attention from investors. UBS and JP Morgan recently lowered their price targets to $36 and $35, respectively, while maintaining neutral ratings. These adjustments come as the stock has fallen significantly from its 52-week high, prompting some analysts to question if the current valuation offers value despite the recent downgrades.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
MSA Safety Upgraded Amid New SCBA Launch. MSA Safety received a Buy upgrade from analysts, who suggest the stock may be undervalued following the launch of a new connected Self-Contained Breathing Apparatus. This product development is seen as a key factor in the company's long-term growth potential. The stock currently trades below the average analyst price target, reflecting a valuation gap that some market participants are watching closely.
Transaction History
| SHC | ▲ Buy | Grant | 14,970 | $0 | 5/22/2026 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 10,307 | $632K | 2/20/2026 | View on chart |
| ROL | ▲ Buy | Grant | 29,340 | $0 | 2/20/2026 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 3,240 | $195K | 2/17/2026 | View on chart |
| ROL | ▲ Buy | Grant | 22,090 | $0 | 2/10/2026 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 7,579 | $487K | 2/10/2026 | View on chart |
| ROL | ▲ Buy | Grant | 33,750 | $0 | 2/20/2025 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 5,326 | $273K | 2/20/2025 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 3,254 | $163K | 2/18/2025 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 7,958 | $366K | 1/1/2025 | View on chart |
| ROL | ▼ Sell | Open Market | 3,331 | $158K | 6/5/2024 | View on chart |
| ROL | ▼ Sell | Open Market | 5,000 | $225K | 4/26/2024 | View on chart |
| ROL | ▼ Sell | Open Market | 5,000 | $231K | 3/13/2024 | View on chart |
| ROL | ▲ Buy | Grant | 35,750 | $0 | 2/20/2024 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 3,372 | $138K | 2/16/2024 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 11,064 | $479K | 1/1/2024 | View on chart |
| ROL | ▼ Sell | Open Market | 12,000 | $489K | 6/12/2023 | View on chart |
| ROL | ▲ Buy | Grant | 29,100 | $0 | 2/16/2023 | View on chart |
| ROL | ▼ Sell | Tax Withholding | 7,522 | $275K | 1/1/2023 | View on chart |
| ROL | ▲ Buy | Grant | 73,186 | $0 | 9/1/2022 | View on chart |
| MSA | ▲ Buy | Grant | 3,655 | $0 | 3/8/2022 | View on chart |
| MSA | ▼ Sell | Tax Withholding | 620 | $80K | 3/8/2022 | View on chart |
| MSA | ▼ Sell | Tax Withholding | 1,590 | $205K | 3/8/2022 | View on chart |
| MSA | ▲ Buy | Grant | 1,439 | $0 | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17
JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.
SHC Downgraded to Underweight by JP Morgan, Price Target Set at $17. JP Morgan lowered its rating on Sotera Health to Underweight and issued a new price target of $17. The downgrade came after the company's recent earnings discussion, which highlighted its current operational performance. Observers also note that the stock has risen about 35% recently, raising questions about its valuation relative to the new target.